PROQR THERAPEUTICS
ProQR Therapeutics is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa. The company's main product candidates are QR-010, QR-110, and QR-313. Its product pipeline includes QRX-704, QRX-504, QRX-421, QRX-323 etc.
PROQR THERAPEUTICS
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2012-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.proqr.com
Total Employee:
101+
Status:
Active
Contact:
0031-0854894932
Total Funding:
359.37 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Euro Apple Mobile Web Clips Icon Google Font API Google Maps Mobile Non Scaleable Content Common Name Invalid ASP.NET
Similar Organizations
Cytoguide
Cytoguide is a biotech company that focuses on the development of combined drugs to treat monocyte- and macrophage-related diseases.
De Western Therapeutics Institute
De Western Therapeutics Institute is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide
Medilink Therapeutics
Medilink Therapeutics is a biotech company focusing on next-generation antibody-drug conjugate Research & development.
Pathios Therapeutics
Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer.
Regulus Therapeutics
Regulus Therapeutics is a clinical stage biopharmaceutical company focused on the development and discovery of microRNA therapeutics.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Tramontane Therapeutics
Tramontane Therapeutics is a gene therapy company creates solutions for common neurological and metabolic illnesses.
UMR 1283-8199
UMR 1283-8199 is a research laboratory that researches type 2 diabetes and related disorders.
Current Employees Featured
Aniz Girach Chief Medical Officer @ ProQR Therapeutics
Chief Medical Officer
2019-01-01
Hilde van Hattum Sr. Scientist Product Characterization and Bioanalytics @ ProQR Therapeutics
Sr. Scientist Product Characterization and Bioanalytics
Theresa Heggie CCO @ ProQR Therapeutics
CCO
Smital Shah Chief Business & Financial Officer @ ProQR Therapeutics
Chief Business & Financial Officer
2018-12-01
Gerrit Dekker Director of Information Technology @ ProQR Therapeutics
Director of Information Technology
2022-08-01
Daniel A. de Boer Founding CEO @ ProQR Therapeutics
Founding CEO
Dinko Valerio Co-Founder and Chairman of the Board @ ProQR Therapeutics
Co-Founder and Chairman of the Board
2012-01-01
Naveed Shams Chief Scientific Officer @ ProQR Therapeutics
Chief Scientific Officer
2020-10-01
Gerard Platenburg CIO and Co-founder @ ProQR Therapeutics
CIO and Co-founder
Founder
Stock Details
Investors List
Rett Syndrome Research Trust
Rett Syndrome Research Trust investment in Grant - ProQR Therapeutics
Eli Lilly
Eli Lilly investment in Post-IPO Equity - ProQR Therapeutics
Pontifax
Pontifax investment in Post-IPO Debt - ProQR Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Series A - ProQR Therapeutics
Sofinnova Partners
Sofinnova Partners investment in Seed Round - ProQR Therapeutics
Official Site Inspections
http://www.proqr.com Semrush global rank: 2.73 M Semrush visits lastest month: 6.4 K
- Host name: 136-144-162-130.colo.transip.net
- IP address: 136.144.162.130
- Location: Eindhoven Netherlands
- Latitude: 51.4513
- Longitude: 5.4009
- Timezone: Europe/Amsterdam
- Postal: 5657
More informations about "ProQR Therapeutics"
ProQR leadership – An experienced team of healthcare …
ProQR's leadership is a strong team with proven track record. Find out who is on our management team, board of directors and scientific advisory board. ... Beam Therapeutics, Kymera Therapeutics, and the Biotechnology Industry …See details»
ProQR - Wikipedia
ProQR was founded in 2012 by chief executive officer (CEO) Daniel A. de Boer and co-founders Henri Termeer, Dinko Valerio and Gerard Platenburg. The initial pipeline of the company was to develop small-molecule drugs or gene therapy that would treat cystic fibrosis (CF). Positive proof of concept (PoC) was achieved in 2016 with the clinical trial of the molecule QR-010 targeting the gene coding for cystic fibrosis transmembrane conductance regulatorSee details»
ProQR Strengthens Leadership with Appointments of CFO and …
16 hours ago LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to …See details»
ProQR Therapeutics - Crunchbase Company Profile & Funding
Organization. ProQR Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ProQR Therapeutics is a biotech …See details»
ProQR Therapeutics appoints Hom as CFO, Lopez as CMO
1 day ago ProQR Therapeutics (PRQR) announced the appointment of Dennis Hom as Chief Financial Officer, CFO, and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer, CMO. …See details»
ProQR Therapeutics (Nasdaq: $PRQR) – Corporate Governance
Download link 20240522-ProQR Board Compensation Policy pdf, 231.19 KB; Download link 20240522-ProQR Equity Incentive Plan pdf, 297.69 KB; Download link 20240522-PNV-Code …See details»
ProQR - businessabc.net
5 days ago ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. History ProQR was founded in 2012 by chief executive officer Daniel de Boer …See details»
ProQR Therapeutics Company Profile - Office Locations ... - Craft
Sep 4, 2024 ProQR Therapeutics has 3 employees across 2 locations and €6.51 m in annual revenue in FY 2023. See insights on ProQR Therapeutics including office locations, …See details»
ProQR Announces Year End 2024 Operating and Financial
Mar 13, 2025 In October 2024, ProQR closed an underwritten public offering of 18,000,000 ordinary shares and a concurrent private placement of 3,523,538 ordinary shares with Eli Lilly …See details»
ProQR Therapeutics CFO Jurriaan Dekkers Steps Down, Dennis …
15 hours ago (RTTNews) - ProQR Therapeutics N.V. (PRQR), a biotechnology company, on Monday announced the stepping down of Chief Financial Officer Jurriaan Dekkers and Chief …See details»
ProQR Therapeutics (PRQR) Company Profile & Description
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company’s products pipeline includes AX-0810 for …See details»
ProQR names new CFO and CMO to bolster RNA editing platform
1 day ago ProQR’s cash and cash equivalents were reported at €149.4 million, providing a stable financial outlook into mid-2027. H.C. Wainwright has raised ProQR’s stock target to …See details»
ProQR Strengthens Leadership with Appointments of CFO and …
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through …See details»
ProQR Therapeutics N.V. (PRQR) - Yahoo Finance Canada
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for …See details»
ProQR Therapeutics Reinforces Its Growth Trajectory with Strategic ...
Dec 10, 2024 ProQR Therapeutics NV (Nasdaq: PRQR), a pioneering company focused on revolutionary RNA therapies supported by its proprietary Axiomer RNA editing technology, has …See details»
ProQR (PRQR) Strengthens Leadership with New CFO and CMO …
ProQR Therapeutics (PRQR, Financial) has strategically enhanced its executive team by appointing Dennis Hom as Chief Financial Officer and Cristina Lopez Lopez, MD, PhD, as …See details»
ProQR Strengthens Leadership with Appointments of CFO and …
16 hours ago ProQR Therapeutics N.V. Investor and media contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 [email protected] or Investor contact: Peter Kelleher …See details»
Embracing Diversity: Why it Matters | ProQR Therapeutics
May 27, 2024 ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum …See details»
Lilly and ProQR to Expand RNA Editing Collaboration - PR Newswire
Dec 22, 2022 Forward Looking Statements for ProQR This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking …See details»
Today marks an expansion of the ProQR and Lilly partnership
Dec 22, 2022 The collaboration, originally announced in September 2021, applied ProQR’s proprietary Axiomer® RNA editing platform to target disorders of the liver and nervous system. …See details»